Key clinical point: Treatment of perimenstrual migraine attacks with lasmiditan was associated with early and sustained freedom from migraine-related pain.
Major finding: Women who received 200 mg lasmiditan vs placebo during perimenstrual migraine attacks were more likely to report freedom from migraine-related pain (odds ratio [OR] 6.04; P < .001) and pain relief (OR 2.29; P = .007) at 2 hours and sustained freedom from pain at 24 hours (OR 11.67; P = .001).
Study details: Findings are from a post hoc analysis of the phase 2 MONONOFU and phase 3 CENTURION trials including 303 women with migraine with or without aura who had ≥1 perimenstrual migraine attacks and were randomly assigned to receive lasmiditan (50, 100, or 200 mg) or placebo.
Disclosures: This study was funded by Eli Lilly and Company . Four authors declared being employees and minor stockholders of Eli Lilly and Company. The other authors reported ties with various sources, including Eli Lilly and Company.
Source: MacGregor EA et al. Efficacy of lasmiditan for the acute treatment of perimenstrual migraine. Cephalalgia. 2022 (Aug 18). Doi: 10.1177/03331024221118929